秦叔逵-话题@MedSci

#秦叔逵#

22篇内容 | 1886人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2130452, encodeId=21c82130452d8, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>、<a href='/topic/show?id=9b41614554a' target=_blank style='color:#2F92EE;'>#李进#</a>教授发现<a href='/topic/show?id=3fca4e359e3' target=_blank style='color:#2F92EE;'>#尼妥珠单抗#</a>联合<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a>可提高<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>患者疗效, objectTitle=ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效, objectType=article, longId=729412, objectId=4900e294125e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220608/60242e4ac3e24371bf3be83904cfc37c.jpg, objectUrl=/article/show_article.do?id=4900e294125e, replyNumber=0, likeNumber=133, createdTime=2023-05-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4900e294125e, moduleTitle=ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4900e294125e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742129, encodeId=f62b1e42129d0, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效, objectType=article, longId=729412, objectId=4900e294125e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4900e294125e, replyNumber=0, likeNumber=96, createdTime=2023-03-01, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4900e294125e, moduleTitle=ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4900e294125e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742128, encodeId=fc831e4212841, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, objectType=article, longId=217674, objectId=aa6321e674ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6321e674ae, replyNumber=0, likeNumber=91, createdTime=2021-10-01, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6321e674ae, moduleTitle=CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6321e674ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742127, encodeId=769a1e421279e, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=CSCO 2020丨秦叔逵院士：原发性肝癌药物治疗研究进展——中国学者的贡献, objectType=article, longId=200997, objectId=c58d20099e35, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58d20099e35, replyNumber=0, likeNumber=55, createdTime=2020-11-20, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58d20099e35, moduleTitle=CSCO 2020丨秦叔逵院士：原发性肝癌药物治疗研究进展——中国学者的贡献, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c58d20099e35)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742126, encodeId=f0e01e4212684, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=72, createdTime=2020-05-21, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742118, encodeId=c84a1e4211839, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, objectType=article, longId=139468, objectId=ee9013946879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9013946879, replyNumber=0, likeNumber=74, createdTime=2019-04-30, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9013946879, moduleTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9013946879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742124, encodeId=8c8d1e421241f, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：肝癌大国的PD-1之路，看免疫疗法如何破冰晚期肝癌治疗!, objectType=article, longId=156744, objectId=9b42156e4404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b42156e4404, replyNumber=0, likeNumber=97, createdTime=2019-10-24, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b42156e4404, moduleTitle=秦叔逵教授：肝癌大国的PD-1之路，看免疫疗法如何破冰晚期肝癌治疗!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b42156e4404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742125, encodeId=22631e4212597, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：击破“癌王”僵局免疫治疗之春破晓而来, objectType=article, longId=157139, objectId=f40d15e13990, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40d15e13990, replyNumber=0, likeNumber=76, createdTime=2019-04-29, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40d15e13990, moduleTitle=秦叔逵教授：击破“癌王”僵局免疫治疗之春破晓而来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40d15e13990)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742120, encodeId=123f1e42120b1, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵：肝胆胰肿瘤，从患者第一次就诊管起来, objectType=article, longId=146048, objectId=eeff1460487c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eeff1460487c, replyNumber=0, likeNumber=67, createdTime=2019-05-16, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeff1460487c, moduleTitle=秦叔逵：肝胆胰肿瘤，从患者第一次就诊管起来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeff1460487c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742119, encodeId=90ce1e4211994, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：回首舒尼替尼十年，期待惠及更多肾癌患者, objectType=article, longId=139927, objectId=b44613992edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b44613992edc, replyNumber=0, likeNumber=72, createdTime=2019-01-19, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b44613992edc, moduleTitle=秦叔逵教授：回首舒尼替尼十年，期待惠及更多肾癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b44613992edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742121, encodeId=c5591e4212128, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=2018 CSCO | 秦叔逵教授：无论是否出现高血压，呋喹替尼均显著延长OS, objectType=article, longId=149366, objectId=6a6e149366c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6e149366c8, replyNumber=0, likeNumber=74, createdTime=2019-02-27, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6e149366c8, moduleTitle=2018 CSCO | 秦叔逵教授：无论是否出现高血压，呋喹替尼均显著延长OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6e149366c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742122, encodeId=e95a1e4212272, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》, objectType=article, longId=149581, objectId=d002149581b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d002149581b6, replyNumber=0, likeNumber=75, createdTime=2019-01-05, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d002149581b6, moduleTitle=【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d002149581b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742123, encodeId=01551e42123a0, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》, objectType=article, longId=149583, objectId=fab914958320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fab914958320, replyNumber=0, likeNumber=69, createdTime=2019-02-28, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fab914958320, moduleTitle=【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab914958320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742116, encodeId=63fa1e42116ab, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响, objectType=article, longId=115046, objectId=611311504698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=611311504698, replyNumber=0, likeNumber=87, createdTime=2017-10-22, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=611311504698, moduleTitle=【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=611311504698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742117, encodeId=719e1e4211789, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：肝癌精准治疗需要加油，药物安全性值得关注, objectType=article, longId=126132, objectId=cb1912613260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1912613260, replyNumber=0, likeNumber=71, createdTime=2018-07-04, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1912613260, moduleTitle=秦叔逵教授：肝癌精准治疗需要加油，药物安全性值得关注, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1912613260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742114, encodeId=162b1e42114b6, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授、王宝成教授专访—肿瘤免疫治疗我们在路上, objectType=article, longId=95646, objectId=f6d19564615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6d19564615, replyNumber=0, likeNumber=87, createdTime=2017-09-11, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6d19564615, moduleTitle=秦叔逵教授、王宝成教授专访—肿瘤免疫治疗我们在路上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6d19564615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742115, encodeId=47821e421156d, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益, objectType=article, longId=103381, objectId=15e41033812f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e41033812f, replyNumber=0, likeNumber=81, createdTime=2018-02-02, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e41033812f, moduleTitle=秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e41033812f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742111, encodeId=1c011e42111e5, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=秦叔逵教授肝癌研究获国际学界广泛认可, objectType=article, longId=40177, objectId=26b7401e75e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26b7401e75e, replyNumber=0, likeNumber=92, createdTime=2015-05-23, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26b7401e75e, moduleTitle=秦叔逵教授肝癌研究获国际学界广泛认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26b7401e75e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742110, encodeId=55aa1e421109d, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=ASCO 2014：“Best of ASCO”秦叔逵教授谈“阿帕替尼治疗晚期胃癌的III期研究”, objectType=article, longId=35967, objectId=87733596e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87733596e6d, replyNumber=0, likeNumber=85, createdTime=2015-01-22, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87733596e6d, moduleTitle=ASCO 2014：“Best of ASCO”秦叔逵教授谈“阿帕替尼治疗晚期胃癌的III期研究”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87733596e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1742112, encodeId=5c131e42112a0, content=<a href='/topic/show?id=dc29e50954f' target=_blank style='color:#2F92EE;'>#秦叔逵#</a>, objectTitle=CSCO 访秦叔逵：提升实力走出国门, objectType=article, longId=40384, objectId=81144038425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81144038425, replyNumber=0, likeNumber=90, createdTime=2015-06-15, rootId=0, userName=lvliquan, userId=148635038868, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81144038425, moduleTitle=CSCO 访秦叔逵：提升实力走出国门, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81144038425)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

秦叔逵

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#秦叔逵#、#李进#教授发现#尼妥珠单抗#联合#吉西他滨#可提高#胰腺癌#患者疗效

ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效

2023-05-06发表于上海

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

ASCO 2022：秦叔逵、李进教授发现尼妥珠单抗联合吉西他滨可提高胰腺癌患者疗效

2023-03-01

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

CSCO 2021：秦叔逵教授报告阿可拉定一线治疗基线较重预后较差晚期肝细胞癌结果

2021-10-01

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

CSCO 2020丨秦叔逵院士：原发性肝癌药物治疗研究进展——中国学者的贡献

2020-11-20

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2020-05-21

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益

2019-04-30

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：肝癌大国的PD-1之路，看免疫疗法如何破冰晚期肝癌治疗!

2019-10-24

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：击破“癌王”僵局免疫治疗之春破晓而来

2019-04-29

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵：肝胆胰肿瘤，从患者第一次就诊管起来

2019-05-16

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：回首舒尼替尼十年，期待惠及更多肾癌患者

2019-01-19

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

2018 CSCO | 秦叔逵教授：无论是否出现高血压，呋喹替尼均显著延长OS

2019-02-27

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》

2019-01-05

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

【2018 CSCO】秦叔逵教授为你解读《CSCO原发性肝癌诊疗指南》

2019-02-28

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响

2017-10-22

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：肝癌精准治疗需要加油，药物安全性值得关注

2018-07-04

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授、王宝成教授专访—肿瘤免疫治疗我们在路上

2017-09-11

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授：乐伐替尼将给中国肝癌患者带来巨大获益

2018-02-02

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

秦叔逵教授肝癌研究获国际学界广泛认可

2015-05-23

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

ASCO 2014：“Best of ASCO”秦叔逵教授谈“阿帕替尼治疗晚期胃癌的III期研究”

2015-01-22

lvliquan (审核中...)

前往app查看评论内容

#秦叔逵#

CSCO 访秦叔逵：提升实力走出国门

2015-06-15

科室
- - 订阅+
  - 更多科室
工具
服务